Ping Zhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ping Zhan has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Alexander T. Teichmann
Sichuan Provincial Center for Gynaecology and Breast Diseases, The Affiliated Hospital of Southwest Medical University, Luzhou, China
1 shared publicationBairong Xia
Department of Gynecological Oncology Anhui Provincial Cancer Hospital Hefei China
1 shared publicationBaolin Li
Department of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Sichuan Province Engineering Technology Research Center of Molecular Diagnosis of Clinical Diseases, Molecular Diagnosis of Clinical Diseases Key Laboratory, Luzhou, Sichuan 646000, P.R. China
1 shared publicationBo Yang
Department of Gynecological Oncology The First Affiliated Hospital of Bengbu Medical University Bengbu China
1 shared publication- Chong Wang
Department of Statistics, Iowa State University
1 shared publication Dali Pu
Sichuan Provincial Center for Gynaecology and Breast Diseases, The Affiliated Hospital of Southwest Medical University, Luzhou, China
1 shared publication
Latest Publications
- 26 August 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (11) , 2776-2785
SHR ‐2004, a Humanized Monoclonal Antibody Targeting Factor XI , for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active‐Controlled Phase 2 Study
This multicenter, randomized, open‐label, exploratory Phase 2 trial assessed SHR‐2004, an anti‐FXI antibody, for venous thromboembolism (VTE) prevention in patients undergoing ovarian cancer surgery—a population at particularly high thrombotic risk conducted at 25 sites in China. Patients with newly diagnosed Stage III–IV or recurrent ovarian cancer scheduled for surgery were randomly assigned (1:1) to receive subcutaneous SHR‐2004 (180 mg on Day 1 and 120 mg on Day 15) or enoxaparin–rivaroxaban (subcutaneous enoxaparin 40 mg once daily during hospitalization, followed by oral rivaroxaban 10 mg once daily after discharge until Day 28). The primary efficacy outcome was the composite of VTE events within 28 days. The primary safety outcome was major bleeding (MB) or clinically relevant nonmajor bleeding (CRNMB) from first dose to 28 days. Between February 19, 2024 and September 17, 2024, 198 patients received assigned treatment (90 with SHR‐2004, 108 with enoxaparin–rivaroxaban) and were included in the safety analysis. Among 181 patients who completed protocol‐mandated ultrasonography, VTE occurred in 11 (12.6%) patients in the SHR‐2004 group and 19 (20.2%) in the enoxaparin–rivaroxaban group (difference −8.4%, 95% CI −19.9 to 3.1) by Day 28. MB/CRNMB rates were similar between groups (SHR‐2004: 2/90 [2.2%]; enoxaparin–rivaroxaban: 2/108 [1.9%]). In this study, SHR‐2004 showed comparable efficacy to enoxaparin–rivaroxaban for preventing postoperative VTE in patients undergoing ovarian cancer surgery, with a similar low risk of MB or CRNMB. The twice‐monthly dosing schedule offers a potential advantage over daily anticoagulation, supporting further investigation in adequately powered Phase 3 trials. Trial Registration: ClinicalTrials.gov identifier: NCT06220123
- 26 August 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (11) , 2776-2785
SHR ‐2004, a Humanized Monoclonal Antibody Targeting Factor XI , for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active‐Controlled Phase 2 Study
This multicenter, randomized, open‐label, exploratory Phase 2 trial assessed SHR‐2004, an anti‐FXI antibody, for venous thromboembolism (VTE) prevention in patients undergoing ovarian cancer surgery—a population at particularly high thrombotic risk conducted at 25 sites in China. Patients with newly diagnosed Stage III–IV or recurrent ovarian cancer scheduled for surgery were randomly assigned (1:1) to receive subcutaneous SHR‐2004 (180 mg on Day 1 and 120 mg on Day 15) or enoxaparin–rivaroxaban (subcutaneous enoxaparin 40 mg once daily during hospitalization, followed by oral rivaroxaban 10 mg once daily after discharge until Day 28). The primary efficacy outcome was the composite of VTE events within 28 days. The primary safety outcome was major bleeding (MB) or clinically relevant nonmajor bleeding (CRNMB) from first dose to 28 days. Between February 19, 2024 and September 17, 2024, 198 patients received assigned treatment (90 with SHR‐2004, 108 with enoxaparin–rivaroxaban) and were included in the safety analysis. Among 181 patients who completed protocol‐mandated ultrasonography, VTE occurred in 11 (12.6%) patients in the SHR‐2004 group and 19 (20.2%) in the enoxaparin–rivaroxaban group (difference −8.4%, 95% CI −19.9 to 3.1) by Day 28. MB/CRNMB rates were similar between groups (SHR‐2004: 2/90 [2.2%]; enoxaparin–rivaroxaban: 2/108 [1.9%]). In this study, SHR‐2004 showed comparable efficacy to enoxaparin–rivaroxaban for preventing postoperative VTE in patients undergoing ovarian cancer surgery, with a similar low risk of MB or CRNMB. The twice‐monthly dosing schedule offers a potential advantage over daily anticoagulation, supporting further investigation in adequately powered Phase 3 trials. Trial Registration: ClinicalTrials.gov identifier: NCT06220123
- Open Access
- 19 March 2026
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 24 (5) , 1-14
Unveiling the mysteries of C1QBP in gynecological tumors (Review)
The morbidity and mortality of gynecological tumors have been increasing globally in recent years. The identification of new biomarkers and drug targets has become an opportunity and challenge in the treatment of these tumor types. In recent years, the role of mitochondrial oxidative phosphorylation in the development of gynecological tumors has attracted attention, and existing studies have shown that complement component 1 Q subcomponent-binding protein (C1QBP) is involved in critical biological processes such as proliferation, migration and invasion of these tumors. However, the specific mechanism and function of C1QBP in gynecological tumors remain unknown and further studies are still needed to reveal its role and clinical application prospects. Therefore, the present review describes the changes and mechanism, such as in the apoptosis and invasion of tumor cells, of C1QBP in cervical, ovarian and endometrial cancer. The present review examines the current research progress on C1QBP in gynecological tumors to provide new ideas and methods for diagnosing and treating this disease.
- 19 March 2026
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 24 (5) , 1-14
Open AccessUnveiling the mysteries of C1QBP in gynecological tumors (Review)
The morbidity and mortality of gynecological tumors have been increasing globally in recent years. The identification of new biomarkers and drug targets has become an opportunity and challenge in the treatment of these tumor types. In recent years, the role of mitochondrial oxidative phosphorylation in the development of gynecological tumors has attracted attention, and existing studies have shown that complement component 1 Q subcomponent-binding protein (C1QBP) is involved in critical biological processes such as proliferation, migration and invasion of these tumors. However, the specific mechanism and function of C1QBP in gynecological tumors remain unknown and further studies are still needed to reveal its role and clinical application prospects. Therefore, the present review describes the changes and mechanism, such as in the apoptosis and invasion of tumor cells, of C1QBP in cervical, ovarian and endometrial cancer. The present review examines the current research progress on C1QBP in gynecological tumors to provide new ideas and methods for diagnosing and treating this disease.
- 16 December 2022
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 307 (4) , 1037-1045
The effectiveness of single ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation in managing placenta accreta spectrum (PAS) disorder
Objective To evaluate the feasibility and effectiveness of single ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation in managing placenta accreta spectrum (PAS) disorder. Materials and methods We retrospectively analyzed 40 PAS patients between April 2017 and October 2021. All the patients received one session of HIFU treatment. Regular follow-up was done after HIFU treatment until normal menstruation returned and placental tissue disappeared. The patient’s reproductive-related outcomes were obtained through telephone interviews. Results The median follow-up time for the 40 patients was 30.50 (15.75–44.00) months and the mean placental tissue elimination time was 45.29 ± 33.32 days. The mean duration of bloody lochia was 13.43 ± 10.01 days, with no incidences of severe bleeding. Notably, Linear regression analysis showed that the residual placenta volume before HIFU was a factor affecting the duration of bloody lochia after HIFU (R2 = 0.284, B = 0.062, P = 0.000). The normal menstrual return time was 58.71 ± 31.14 days. One (2.50%) patient developed an infection. Two (5.00%) patients were subjected to ultrasound-guided suction curettage for persistent vaginal discharge for more than one month without infection. Notably, 7 of the 18 patients who expressed reproductive plans became pregnant during the 4 to 53 months of follow-up without placental abnormalities. The remaining 11 patients were on contraceptives. Conclusions Single HIFU is an effective treatment option for managing PAS. However, future studies on further treatment strategies to reduce complications and promote patient recovery after HIFU ablation are desirable.
- 16 December 2022
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 307 (4) , 1037-1045
The effectiveness of single ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation in managing placenta accreta spectrum (PAS) disorder
Objective To evaluate the feasibility and effectiveness of single ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation in managing placenta accreta spectrum (PAS) disorder. Materials and methods We retrospectively analyzed 40 PAS patients between April 2017 and October 2021. All the patients received one session of HIFU treatment. Regular follow-up was done after HIFU treatment until normal menstruation returned and placental tissue disappeared. The patient’s reproductive-related outcomes were obtained through telephone interviews. Results The median follow-up time for the 40 patients was 30.50 (15.75–44.00) months and the mean placental tissue elimination time was 45.29 ± 33.32 days. The mean duration of bloody lochia was 13.43 ± 10.01 days, with no incidences of severe bleeding. Notably, Linear regression analysis showed that the residual placenta volume before HIFU was a factor affecting the duration of bloody lochia after HIFU (R2 = 0.284, B = 0.062, P = 0.000). The normal menstrual return time was 58.71 ± 31.14 days. One (2.50%) patient developed an infection. Two (5.00%) patients were subjected to ultrasound-guided suction curettage for persistent vaginal discharge for more than one month without infection. Notably, 7 of the 18 patients who expressed reproductive plans became pregnant during the 4 to 53 months of follow-up without placental abnormalities. The remaining 11 patients were on contraceptives. Conclusions Single HIFU is an effective treatment option for managing PAS. However, future studies on further treatment strategies to reduce complications and promote patient recovery after HIFU ablation are desirable.
- 1 November 2016
- Published by Elsevier in The American Journal of Surgery
- Vol. 212 (5) , 912-916
Long-term follow-up of anterior approach preperitoneal hernia repair using the Kugel patch
- 1 November 2016
- Published by Elsevier in The American Journal of Surgery
- Vol. 212 (5) , 912-916
Long-term follow-up of anterior approach preperitoneal hernia repair using the Kugel patch
- 24 September 2015
- Published by Springer Nature in Mycopathologia
- Vol. 181 (1-2) , 29-39
Combination of Estrogen and Immunosuppressive Agents to Establish a Mouse Model of Candidiasis with Concurrent Oral and Vaginal Mucosal Infection
Mouse model is an appropriate tool for pathogenic determination and study of host defenses during the fungal infection. Here, we established a mouse model of candidiasis with concurrent oral and vaginal mucosal infection. Two C. albicans strains sourced from clinical candidemia (SC5314) and mucosal infection (ATCC62342) were tested in ICR mice. The different combinational panels covering estrogen and immunosuppressive agents, cortisone, prednisolone and cyclophosphamide were used for concurrent oral and vaginal candidiasis establishment. Prednisolone in combination with estrogen proved an optimal mode for concurrent mucosal infection establishment. The model maintained for 1 week with fungal burden reached at least 105 cfu/g of tissue. This mouse model was evaluated by in vivo pharmacodynamics of fluconazole and host mucosal immunity of IL-17 and IL-23. Mice infected by SC5314 were cured by fluconazole. An increase in IL-23 in both oral and vaginal homogenates was observed after infection, while IL-17 only had a prominent elevation in oral tissue. This model could properly mimic complicated clinical conditions and provides a valuable means for antifungal assay in vivo and may also provide a useful method for the evaluation of host–fungal interactions.
- 24 September 2015
- Published by Springer Nature in Mycopathologia
- Vol. 181 (1-2) , 29-39
Combination of Estrogen and Immunosuppressive Agents to Establish a Mouse Model of Candidiasis with Concurrent Oral and Vaginal Mucosal Infection
Mouse model is an appropriate tool for pathogenic determination and study of host defenses during the fungal infection. Here, we established a mouse model of candidiasis with concurrent oral and vaginal mucosal infection. Two C. albicans strains sourced from clinical candidemia (SC5314) and mucosal infection (ATCC62342) were tested in ICR mice. The different combinational panels covering estrogen and immunosuppressive agents, cortisone, prednisolone and cyclophosphamide were used for concurrent oral and vaginal candidiasis establishment. Prednisolone in combination with estrogen proved an optimal mode for concurrent mucosal infection establishment. The model maintained for 1 week with fungal burden reached at least 105 cfu/g of tissue. This mouse model was evaluated by in vivo pharmacodynamics of fluconazole and host mucosal immunity of IL-17 and IL-23. Mice infected by SC5314 were cured by fluconazole. An increase in IL-23 in both oral and vaginal homogenates was observed after infection, while IL-17 only had a prominent elevation in oral tissue. This model could properly mimic complicated clinical conditions and provides a valuable means for antifungal assay in vivo and may also provide a useful method for the evaluation of host–fungal interactions.